Keyphrases
Duchenne muscular Dystrophy
100%
Quality of Life
100%
Prospective Cohort Study
100%
Glucocorticoid Therapy
100%
Quality of Survival
100%
Disease Progression
60%
Upper Limb
60%
Clinically Significant
40%
Risk Reduction
40%
Across the Lifespan
40%
Risk of Death
40%
Rehabilitation Research
20%
Disability Studies
20%
Arthritis
20%
Long-term Benefit
20%
Musculoskeletal Disorders
20%
Hand Function
20%
Muscular Dystrophy
20%
Duchenne
20%
Prednisone
20%
Standard of Care
20%
Treatment Duration
20%
U.S. Department of Education
20%
Prednisolone
20%
Skin Diseases
20%
Odds Ratio
20%
Deflazacort
20%
Male Patients
20%
Glucocorticoid Use
20%
Treatment Group
20%
National Institutes of Health
20%
Stair Climbing
20%
Ambulation
20%
10-year Follow-up
20%
All Diseases
20%
US Department of Defense
20%
Recruitment Period
20%
Hand-to-mouth
20%
Kaplan-Meier Analysis
20%
Disease-related
20%
Medicine and Dentistry
Quality of Life
100%
Duchenne Muscular Dystrophy
100%
Glucocorticoid
100%
Prospective Cohort Study
100%
Disease Exacerbation
27%
Upper Limb
27%
Lifespan
18%
Mouth
9%
Muscular Dystrophy
9%
Hand Function
9%
Arthritis
9%
Kaplan Meier Method
9%
Treatment Duration
9%
Skin Disease
9%
Limb Disease
9%
Prednisone
9%
Prednisolone
9%
Deflazacort
9%
Odds Ratio
9%
Diseases
9%
Treatment Group
9%
Pharmacology, Toxicology and Pharmaceutical Science
Prospective Cohort Study
100%
Duchenne Muscular Dystrophy
100%
Glucocorticoid
100%
Disease Exacerbation
27%
Diseases
18%
Arthritis
9%
Muscular Dystrophy
9%
Limb Disease
9%
Prednisone
9%
Prednisolone
9%
Deflazacort
9%
Treatment Group
9%